Search research articles
Contact Us
Filters
Showing results (251-260 of 265) with videos related to
Page
of 27
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
R Colomer, E Alba, A González-Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2003
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial
V Alberola, C Camps, M Provencio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
H Cortes-Funes, C Gomez, R Rosell, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 17, 2002
Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001
J R Fischer, P Baas, H D Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
S Peters, R Camidge, R Dziadziuszko, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging
|
April 19, 2024
Training in Cognitive Reappraisal Normalizes Whole-Brain Indices of Emotion Regulation in Borderline Personality Disorder
Bryan T Denny, Richard B Lopez, E Lydia Wu-Chung, et al.
ESMO Open
|
February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
S Michels, B Massutí, I Vasyliv, et al.
ESMO Open
|
June 26, 2022
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
L Rojas, D Mayorga, A Ruiz-Patiño, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 265) with videos related to
Sort By:
Page
of 27
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2010
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
R Colomer, E Alba, A González-Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2003
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial
V Alberola, C Camps, M Provencio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
H Cortes-Funes, C Gomez, R Rosell, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 17, 2002
Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001
J R Fischer, P Baas, H D Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study
S Peters, R Camidge, R Dziadziuszko, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging
|
April 19, 2024
Training in Cognitive Reappraisal Normalizes Whole-Brain Indices of Emotion Regulation in Borderline Personality Disorder
Bryan T Denny, Richard B Lopez, E Lydia Wu-Chung, et al.
ESMO Open
|
February 13, 2024
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
S Michels, B Massutí, I Vasyliv, et al.
ESMO Open
|
June 26, 2022
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
L Rojas, D Mayorga, A Ruiz-Patiño, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Page
of 27